scFv(CD19)-CD28-OX40-CD3zeta CAR-T Lentivirus

In recent years, cell therapies, particularly CAR-T cells, have achieved success in clinical trials for a variety of cancers, including multiple myeloma, leukemia, lymphoma, and neuroblastoma. This has revolutionized cancer treatment and remains one of the most cutting-edge and exciting areas of medical research. The CAR-T production process primarily involves initial isolation and enrichment of T cells, T cell activation, T cell expansion, CAR gene transfer using viral or non-viral vector systems, ex vivo CAR-T cell expansion, and final processing and cryopreservation of the resulting cell product. The viral vector that delivers the specific CAR gene into T cells is a key raw material in the entire production process.

Currently, most CAR-T cell production utilizes lentivirus as a gene delivery vector. Lentiviruses are derived from the human immunodeficiency virus and are a type of retrovirus. Unlike adenoviruses and adeno-associated viruses, lentiviruses can mediate the integration of exogenous genes into the host genome, enabling sustained and stable gene expression. Immune cells such as T cells, NK cells, and DCs, as well as neural cells and stem cells, can be genetically modified using lentiviruses to achieve therapeutic effects. Lentiviruses can also serve as delivery vehicles for gene editing or as vaccine vectors. Lentiviral vectors have broad prospects for clinical application, with major indications including tumors, genetic diseases, metabolic diseases, central nervous system diseases, and ophthalmic diseases.